Pfizer has expanded its range of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). This expansion includes ABRYSVO™, Pfizer’s bivalent RSV prefusion F (RSVpreF) vaccine, which is now recommended as a maternal immunization for respiratory syncytial virus (RSV). This is the first autumn season in which individuals are eligible to receive Pfizer vaccines for protection against RSV, COVID-19, and pneumococcal pneumonia.
The ACIP has recommended maternal RSV vaccination for pregnant individuals between the 32nd and 36th weeks of gestation to prevent RSV lower respiratory tract infections in infants. This provisional recommendation will become official after review and adoption by the CDC director. This development follows the FDA’s approval of ABRYSVO in August as the first maternal vaccine for preventing lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants up to six months old.
Pfizer’s actions align with the increasing importance of maternal immunization to safeguard both mothers and infants. This latest recommendation expands Pfizer’s portfolio of respiratory vaccines, encompassing RSV, COVID-19, and pneumococcal pneumonia, while emphasizing the company’s dedication to providing accessible, high-quality vaccines for various infectious diseases.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
